一本到高清视频不卡dvd,高清一本dvd,一本道av,日本一本二本三区无码

  • <delect id="eyjux"><rp id="eyjux"><td id="eyjux"></td></rp></delect>
  • <acronym id="eyjux"></acronym>
    
    

    <object id="eyjux"><strong id="eyjux"></strong></object>

    www.taishunjiguang.com 提示:

    本信息僅供醫學專業人士參考,如果您是醫學專業人士,請點擊確定后進入。 如果不是,請點擊取消。

    取消 確定

    Products and services

    In 3SBio, meeting the needs of patients is the core of all actions.

    Our global list of drug combinations

    The following is a list of products listed by our company, which is only for medical professionals to refer to.

    TPIAO (Recombinant human thrombopoietin (rhTPO))

    In 2005, TPIAO was listed and has been approved by the NMPA for two indications that are the treatment of chemotherapy-induced thrombopenia (approved in 2005) and immune thrombocytopenia (ITP) (approved in 2010), which is included in the National Medical Insurance Catalogue as a Category B drug of western medicine.

    Indication Manufacturing base Dosage form & Dosage

    Treatment for chemotherapy-induced thrombocytopenia (CIT);
    Treatment for immune thrombocytopenia (ITP).

    Shenyang manufacturing base

    7500 U/1 ml; 15000 U/1 ml

    Cipterbin (Inetetamab for?Injection)

    Cipterbin was formally approved in June 2020 as the first innovative anti-HER2 monoclonal antibody in China with the engineered Fc region, optimized production process and a stronger ADCC effect. Research showed that in combination with chemotherapy drugs, it can significantly reduce the risk of disease progression in patients with HER2-positive metastatic breast cancer, improve the objective response rate, and prolong the progression-free survival of the patients.

    Indication Manufacturing base Dosage form & Dosage
    This product is indicated, in combination with vinorelbine, for the treatment of patients with HER2-positive metastatic breast cancer, who have received one or more chemotherapy regimens. Shanghai manufacturing base 50mg/bottle

    Intefen (Recombinant human interferon (α-2a))

    In April 1995, Intefen was approved to be manufactured by NMPA.In December 1995, Intefen was launched and is included in the National Medical Insurance Catalogue as a Category B drug.

    Indication Manufacturing base Dosage form & Dosage
    Treatment of lymphatic or hematopoietic malignancies and viral infections: adult chronic hepatitis B, acute and chronic hepatitis C and condyloma acuminata. Shenyang manufacturing base Injection - 1,000,000 IU/ml, 3,000,000 IU/ml, 5,000,000 IU/ml;
    Freeze-dried powder - 1,000,000 IU/ml, 3,000,000 IU/ml, 5,000,000 IU/ml.

    Inleusin (Recombinant human interleukin2 (IL-2))

    In June 1995, NMPA production approval documents were obtained for Inleusin. This product was launched in March 1996 and is included in the National Medical Insurance Catalogue as a Category B drug.

    Indication Manufacturing base Dosage form & Dosage
    Treatment of renal cell carcinoma, melanoma, thoracic fluid build-up caused by cancer, and tuberculosis. Shenyang manufacturing base 100,000 IU/bottle; 200,000 IU/bottle; 500,000 IU/bottle; 1,000,000 IU/bottle
  • <delect id="eyjux"><rp id="eyjux"><td id="eyjux"></td></rp></delect>
  • <acronym id="eyjux"></acronym>
    
    

    <object id="eyjux"><strong id="eyjux"></strong></object>

    一本到高清视频不卡dvd,高清一本dvd,一本道av,日本一本二本三区无码

    品牌简介

    一本到高清视频不卡dvd,高清一本dvd,一本道av,日本一本二本三区无码